05/21/2026
Must read!!!
Osteoarthritis, NSAIDs and Medical Cannabis
Osteoarthritis (OA) is the most common form of arthritis and one of the leading causes of chronic pain and disability in adults. The condition affects approximately 32.5 million US adults, making OA the most common form of arthritis. Its prevalence is rising due to an aging and more obese population, with total economic burdens of OA exceeding $136.8 billion annually.
OA is a degenerative joint disease characterized by the progressive loss of cartilage in affected, previously worn or damaged joints from chronic inflammation, resulting in stiffness and pain, which is exacerbated with physical activity or weight bearing. The knees, hips, hands, and spine are most commonly involved. Current orthopedic guidelines emphasize low impact exercise, weight reduction when appropriate, physical therapy, the use of assistive devices (cane, walker, etc.), and prescribed medications as the core of treatment. Surgical replacement or fusion may be considered for severe disease in specific joints.
The conventional pharmacologic approach to OA often includes acetaminophen, nonsteroidal antiinflammatory medications (NSAIDs), topical NSAIDs, duloxetine (Cymbalta), intra-articular (into the joint) steroid injections, and opioids. Of these, NSAIDs remain the most common oral drug class prescribed for day-to-day symptom control.
NSAIDs: nonsteroidal antiinflammatory medications
Topical and oral NSAIDs are widely used because they can reduce inflammation which improves pain and physical function, but they are associated with potentially severe side effects, particularly when used chronically.
Gastrointestinal ulceration and bleeding affects 2-4% of patients taking NSAIDs for a year, four times higher than non-users, with a mortality rate of 21% for GI bleeds which occur in patients using NSAIDs. Chronic NSAID use resulting in serious GI bleeding is estimated to account for at least 32,000 hospitalizations and 3,200 deaths annually in the US.
Cardiovascular events, including myocardial infarction and stroke, with long term or high dose NSAID therapy are estimated to cause 7-9 non-fatal cardiovascular events and 2 deaths per 1000 patients per year; patients older than 64 years old with a history of heart disease, stroke, hypertension, or peptic ulcers are at the highest risk. The FDA has strengthened warnings for the NSAID drug class to reflect that the increased cardiovascular risk may begin early in treatment, and further increase with higher doses and long term use.
Long term NSAID use can also damage the kidneys, resulting in diminished renal function that limits their use in patients who develop this side effect. Fluid retention and edema in the lower extremities commonly occurs. GI discomfort, bruising and freely bleeding after minor injuries are frequently reported side effects.
Medical Cannabis
Although NSAIDs are an effective pharmacologic therapy for many patients with OA, the toxicity profile and side effects of this class of drugs limits their use or raises significant concerns for many others. Medical cannabis may provide an effective addition or alternative to NSAID medications.
The phytochemicals, chemicals produced by a plant, of interest produced by cannabis consist of terpenes and cannabinoids, which modulate homeostatic regulatory systems in the body that control all aspects of maintaining life. The cannabinoids modulate the body’s endocannabinoid system (ECS), which is significant in OA, as the ECS is involved in the regulation of pain signaling, sleep, mood, immune system activity, and inflammation. Medical cannabis can reduce pain amplification, improve sleep, decrease immune system inflammatory signaling, and joint inflammation. The addition of medical cannabis therapy may lessen reliance on medications with more serious toxicity, or be used as an alternative to NSAIDs for patients with contraindications to their use.
Cannabidiol (CBD)
CBD interacts indirectly with CB2 endocannabinoid system receptors and other signaling pathways involving TRPV1, serotonin receptors, immune signaling, oxidative stress, and cytokine regulation. These systems are involved in modulating the immune system and inflammatory responses; CBD produces a reduction in inflammatory tone, decreasing joint inflammation and the symptoms of osteoarthritis.
Cannabigerol (CBG)
CBG interacts directly with the CB2 receptors, making it particularly useful in patients with higher levels of inflammation from OA or have autoimmune arthritis. The combined use of CBD with CBG works to decrease inflammation through multiple chemical pathways producing a stronger response; early studies and clinical experience demonstrate that the combination is usually more effective than CBD or CBG used alone. CBG should be used in a 1:1 ratio with CBD.
Tetrahydrocannabinol (THC)
THC also has a role in the management of OA, particularly when pain is severe, sleep is disrupted, or central pain amplification is prominent. In OA, THC is rarely the best starting point by itself, as it does not address inflammation as well as CBD and CBG. A more practical approach is to begin with CBD-predominant formulations, adding low-dose THC as needed for pain control and sleep support. In clinical practice, a reasonable starting framework is often CBD:THC in the range of 20:1 to 10:1. When the inflammatory burden is especially high, some clinicians favor a three-part formula such as CBD:CBG:THC of roughly 10:10:1 to 5:5:1, then titrate from there. These are practical starting ratios rather than rigid evidence-based standards, and the goal is always the same: meaningful relief with minimal side effects.
Terpenes
The terpene constituents of cannabis play an important role. Full-spectrum whole plant products provide better effects than single-molecule isolates because of phytochemical synergy which occurs between these molecules, often referred to as the entourage effect. The effect produced by the combination of phytochemicals is greater than the sum of the individual effects; they potentiate each other’s effectiveness.
Beta-caryophyllene is particularly important because it is a CB2 receptor activating phytochemical, with anti-inflammatory and analgesic activity, making it highly relevant in inflammatory pain conditions like OA. Myrcene has demonstrated anti-inflammatory and analgesic effects in inflammatory joint disease models, and may also help with pain, stiffness and muscle relaxation. Additional terpenes to consider include linalool, which may support sleep and calm pain-related anxiety, limonene, which may improve mood and coping in chronic pain, and pinene and humulene for antiinflammatory effects.
Dosage Forms
Inhaled cannabis, through combustion or vaporization, provides rapid but short lived effects, making it a poor choice for addressing the 24/7 inflammation and pain symptoms of OA. In addition, most inhaled cannabis preparations are heavily THC dominant containing very little CBD or CBG. Using primarily THC results in suboptimal inflammation and pain control compared to preparations containing high levels of CBD and CBG.
Sublingual elixirs are the most practical choice for baseline OA management. Compared with inhaled cannabis, they generally provide a longer duration of action. Compared with standard edibles, sublingual and oromucosal administration are more reliably absorbed to offer more consistent effects, with less variability than oral ingestion using edibles. This makes sublingual dosing especially useful in OA, where the therapeutic goal is steady, predictable, long lasting inflammation reduction and symptom relief.
A practical starting elixir dose for a cannabis-naive OA patient is often 12.5 to 25 mg of full spectrum CBD with 0.25 to 2.5 mg THC twice daily. Maintain the starting dose for several days, then increase the dose by 25-50% if required every 4 to 7 days until adequate symptom improvement is observed.
For edibles, the starting dose should usually be lower and more conservative because oral THC absorption is slower and more variable. Consuming food containing fat prior to dosing is suggested as it will improve gut absorption of cannabinoids. A practical starting point is 1.25 to 2.5 mg THC, preferably paired with 25 mg of CBD every 12 hours. Maintain the starting dose, then increase the dose by 25-50% if required every 4 to 7 days until adequate symptom improvement is observed. The clinical goal is not to reach a predetermined dose, but to identify the lowest effective dose that improves pain, stiffness, sleep, and function without causing cognitive impairment.
In Summary
Medical cannabis may be a valuable adjunct in osteoarthritis, especially for patients limited by NSAID toxicity, poor sleep, persistent inflammatory pain, or desire to reduce exposure to medications with higher cardiovascular and gastrointestinal risk. CBD provides the anti-inflammatory foundation, CBG increases the anti-inflammatory effects when inflammation is severe, and THC potentiates the effects of other cannabinoids while adding analgesia and sleep support when needed. Terpenes such as beta-caryophyllene and myrcene may further improve symptom control. When carefully titrated to an effective dose, full-spectrum sublingual formulations usually provide the best balance of duration, consistency, and tolerability.
